

Roma, 21/10/2021

Caro socio,

l'IG-IBD è una Società di rilievo nell'ambito nazionale ed internazionale, con progetti estremamente interessanti e obiettivi molto validi nel medio e lungo termine. Credo che ciascuno di noi debba mettersi al servizio della Società, nella quale ogni gastroenterologo che si occupa di IBD ha possibilità di crescere e far crescere gli altri.

Mi propongo come membro del Comitato Direttivo, perché credo di poter dare un contributo importante all'IG-IBD sotto vari aspetti, mutuando anche l'esperienza maturata in anni di coinvolgimento attivo nella ECCO, e dopo il duro lavoro fatto per 4 anni nel coordinamento del Comitato Scientifico IG-IBD.

Se sarò ritenuto all'altezza di far parte del Comitato Direttivo, lavorerò con impegno per i seguenti obiettivi:

1 Obiettivi generali

1.1 Standardizzazione di qualità dei Centri IBD in Italia

Ho coordinato per la ECCO un progetto di definizione di parametri minimi di qualità delle cure che devono essere garantiti ad ogni paziente, e dei requisiti indispensabili per qualificare un Centro di riferimento. Tale proposta si è concretizzata in un documento (ECCO Position Paper) che ha proposto una lista di parametri minimi di qualità che dovranno essere presenti in ogni Centro IBD. Uno dei miei obiettivi sarà quello di lavorare anche a livello italiano per adattare questo progetto alla realtà italiana, facendo sì che l'IG-IBD si faccia garante della qualità dei Centri associati. Questo è un bene per i pazienti, che potranno afferire a Centri di riferimento certificati, e un bene per i Centri, perché servirà da stimolo per mantenersi a livelli di eccellenza in maniera duratura.

1.2 Promozione di network Centri IBD

Sulla base della standardizzazione dei Centri sopra descritto, mi impegnerò perché a livello locale e nazionale, si promuova la collaborazione tra Centri a basso ed alto volume di pazienti cosicché si crei una rete collaborativa di assistenza che sfrutti al massimo le varie competenze e risorse disponibili nelle nostre Unità. Questo servirà a limitare la migrazione dei pazienti verso Centri lontani dal proprio domicilio e a fornire ai Centri con meno possibilità tutto il supporto da parte dei grandi Centri di riferimento più vicini.

1.3 Collaborazione con la ECCO e con le altre Società IBD in ambito europeo

La IG-IBD ha avviato un'ottima collaborazione con il GETAID e con altre Società di altre nazioni. Nel mio periodo da Chair del Comitato Scientifico IG-IBD, ho proposto e messo su una collaborazione scientifica all'interno del gruppo del 4Nations, in maniera tale da poter proporre studi multicentrici congiunti tra GETAID, GEDII, GETECCU e IG-IBD.

A livello ECCO, siamo una delle Nazioni più attive, con persone di alto livello nei vari Comitati, ma serve una maggiore collaborazione e una maggiore attenzione alle attività che verranno portate avanti a livello ECCO. Mi impegnerò perché l'IG-IBD abbia la possibilità di proporre e sfruttare l'apporto di persone meritevoli che possano avere voce a livello europeo.

1.4 Criteri oggettivi e trasparenti di scelta

L'IG-IBD è chiamata a scegliere e valutare molte persone per vari compiti, dai Comitati, alle Commissioni, ai Relatori di Corsi e Congressi, ai partecipanti al corso ECCO. Uno dei miei obiettivi è

quello di stabilire criteri oggettivi e validi per tutti, basati su meriti e CV, in maniera tale da rendere tali procedure snelle e trasparenti, in linea già con quanto la Società sta facendo, per esempio, con la valutazione degli studi clinici IG-IBD e con la selezione dei membri del prossimo Comitato Scientifico.

1.5 Ottimizzazione del lavoro del Direttivo

Al momento, l'impostazione del Consiglio Direttivo non prevede particolari compiti per ciascuno, se non per il Segretario. Questo può creare un po' di rallentamenti nell'attività del Comitato. Sull'esempio della ECCO, proporrò di formalizzare un membro del Direttivo che faccia da referente per lo Scientifico e uno per l'Educazionale, in maniera tale da avere mandato dal Direttivo di gestire le normali attività dei due Comitati in maniera da rendere tutto più veloce e lineare, e senza dover aspettare il parere di tutto il Direttivo. Proporrò inoltre che un membro faccia da Liason Officer insieme al Segretario per poter facilitare anche i rapporti con i vari partners di IG-IBD.

2) Obiettivi scientifici

Promozione e supporto di studi IG-IBD multicentrici prospettici.

Il Comitato Scientifico ha portato avanti una rivoluzione positiva nella gestione degli studi clinici. Ad oggi, la sottomissione, l'approvazione e la conduzione degli studi clinici tiene conto soprattutto della qualità scientifica e della copertura dei costi, oltre allo spirito di collaborazione. Continuerò a supportare il più possibile il Comitato Scientifico su questa linea, in particolare nel controllo del rigore metodologico degli studi, del rispetto dei tempi, della responsabilità dei promotori e degli sperimentatori e della corretta e proficua gestione dei fondi.

Come Chair del Comitato Scientifico ho messo su un sistema di registro dei pazienti inseriti negli studi per poter implementare la facilità con cui si portano avanti gli studi IG-IBD. Ho anche lavorato per il reclutamento di una Clinical Research Assistant (dr.ssa Carola Lauritano) che ha aiutato enormemente i Centri a portare avanti gli studi proposti. Sarà mia cura che questa struttura rimanga o, se necessario, venga implementata. Nell'ultimo anno, la produzione scientifica IG-IBD ha raggiunto il record assoluto di pubblicazioni ed impact factor in tutta la storia della nostra Società

Linee guida IBD italiane

È importante che le linee guida ECCO siano adattate alla realtà italiana, in questo l'IG-IBD gioca un ruolo chiave. Mi impegnerò, sulla base dell'esperienza che molti Soci hanno già con le linee guida ECCO su 2 punti:

- Produzione di linee guida italiane che non riproducano fedelmente quelle della ECCO, ma che siano indispensabili alla realtà italiana
- Organizzare in maniera più snella i gruppi di lavoro, in maniera tale da facilitare il compito dei leaders nella stesura e nel completamento delle linee guida entro i tempi prefissati.

3) Obiettivi formativi

Scelta dei relatori e dei Centri per eventi formativi

L'attuale assetto di corsi e opportunità formative proposti dall'IG-IBD è ampio e di alta qualità. Proporrò anche qui di ottimizzare la scelta dei relatori e dei Centri ospitanti tenendo conto della pluralità di offerta a livello italiano, della necessità di dare opportunità di crescita e visibilità ai piccoli e medi Centri, ma garantendo anche parametri di scelta basati su CV, esperienza riconosciuta, autorevolezza scientifica e trasparenza di giudizio.

Proposta di corsi

Credo che IG-IBD debba dare la possibilità, soprattutto ai giovani in formazione, di confrontarsi con aspetti che non vengono sistematicamente insegnati nei corsi Universitari. Proporrò al Comitato Educazionale, come già fatto con la Y-ECCO per gli educational workshops, di valutare la possibilità di fornire momenti formativi su:

- metodologia di ricerca clinica (dall'ipotesi scientifica alla pubblicazione)
- presentazione e discussione di dati scientifici, soprattutto legati agli studi IG-IBD
- costruirsi una carriera nelle IBD
- gestione di risorse sanitarie e management sanitario

Spero di poter contare sul tuo supporto per portare avanti questi obiettivi.
Un caro saluto

A handwritten signature in black ink, appearing to read "Ronald Fournier". The signature is fluid and cursive, with the first name "Ronald" written in a larger, more prominent script than the last name "Fournier".

Curriculum vitae

INFORMAZIONI PERSONALI

Gionata Fiorino
via Vincenzo Tizzani 28, 00151 Roma
gionataf@gmail.com

Siti web

it.linkedin.com/pub/gionata-fiorino/35/7b9/897/
<http://www.humanitas.it/pazienti/info/i-nostrimedici/302-fiorino-gionata>

Sesso Maschio

Data di nascita 24/10/1979

Nazionalità Italiana

Posizione lavorativa Esperienza lavorativa

17/06/2019–Oggi

Ricercatore Universitario in Gastroenterologia - RDTA

Ricercatore Universitario in Gastroenterologia

Dipartimento di Scienze Biomediche, Humanitas University, Pieve Emanuele, Milano (Italia)

01/01/2017–Oggi

Aiuto Gastroenterologo, specialista in IBD

IRCCS Humanitas

via Manzoni 56, 20089 Rozzano (Italia)

Gestione clinica dei pazienti con IBD. Ricerca clinica in IBD.

28/07/2017–17/06/2019

Professore a contratto in Gastroenterologia

Dipartimento di Scienze Biomediche, Humanitas University, Pieve Emanuele, Milano (Italia)

01/01/2010–31/12/2016

Assistente in Gastroenterologia, specialista in IBD

IBD Center, Dept. of Gastroenterology, IRCCS Humanitas

via Manzoni 56, 20089 Rozzano (Italia)

Gestione clinica dei pazienti con IBD. Ricerca clinica in IBD.

01/09/2008–30/04/2009

Fellow in Ricerca Clinica

IRCCS Humanitas

via Manzoni 56, 20089 Rozzano (Italia)

Ricerca clinica in IBD.

01/05/2005–31/08/2008

Sostituto Medico di Medicina Generale

00100 Roma (Italia)

Medicina generale

EDUCATION AND TRAINING

01/01/2010–31/12/2012

Philosophiae Doctor

Università di Messina, Messina (Italia)

Epatogastroenterologia dell'età evolutiva e dell'adulto

Livello 6 ISCED

01/11/2005–19/11/2009

Specialista in Gastroenterologia

Sapienza, Università di Roma, Roma (Italia)

Gastroenterologia

Livello 6 ISCED

19/10/1998–28/10/2004

Laurea in Medicina e Chirurgia

Università Cattolica del Sacro Cuore - Roma

Largo Gemelli 1, 00168 Roma (Italia)

Livello 5B ISCED

01/09/1993–31/07/1998

Licenza liceale

Liceo Classico "Cagnazzi"

Piazza Zanardelli, 70022 Altamura (Italia)

Livello 3B ISCED

19/10/2017–20/10/2017

Corso Avanzato di Management in Gastroenterologia e Immunologia

EQF level 8

LIUC University, Castellanza (Italia)

- Gestione delle risorse sanitarie, impatto sul budget

- Capacità di presentazione e negoziazione

- Aspetti legali nella pratica clinica

11/2011–03/2012

Corso avanzato su revisioni sistematiche, metanalisi e

produzione linee guida.

Cochrane Collaboration, Istituto Mario Negri - Università di Milano, Milano (Italia)

- Revisione sistematica
- Ricerca di letteratura
- Valutazione della qualità dei dati
- Estrazione e meta-analisi dei dati
- Metodologia GRADE
- Valutazione dell'evidenza scientifica
- Produzione di consenso e linee guida

09/2008

Master Class in Crohn's Disease

Experimental Medicine Division - Università di Oxford, Oxford (United Kingdom)

09/2007

Master Class in Ulcerative Colitis

Experimental Medicine Division - Università di Oxford, Oxford (United Kingdom)

04/2007-06/2007

Corso Avanzato di Endoscopia e Videocapsula Endoscopia.

Università Cattolica del Sacro Cuore, Roma (Italia)

09/2004-10/2004

Training in Gastroenterologia, Endoscopia Digestiva e Proctologia

Bichat-Claude Bernard Hospital, Paris (France)

03/2004

Training in Gastroenterologia, Endoscopia Digestiva e Proctologia

Bichat-Claude Bernard Hospital, Paris (France)

06/09/2003-31/10/2003

Training in Gastroenterologia, Endoscopia Digestiva e Proctologia

Bichat-Claude Bernard Hospital, Paris (France)

19/09/2002-19/10/2002

Training in Gastroenterologia, Endoscopia Digestiva e Proctologia

Bichat-Claude Bernard Hospital, Paris (France)

COMPETENZE PERSONALI

Lingua madre

Italiano

Lingue straniere

	COMPRESIONE		PARLATA		SCRITTA
	Ascolto	Letture	Comprensione	Capacità di parlare	
Inglese	C1	C2	C1	C1	C2
Francese	B2	B2	B1	B1	A2
Spagnolo	B2	B2	A2	A2	A2
Olandese	A1	A2	A1	A2	A2

Livelli: A1 e A2: Base - B1 e B2: Indipendente - C1 e C2: Fluente

Common European Framework of Reference for Languages – Self-assessment grid

Capacità di comunicazione

2010-oggi: Relatore e Membro della Faculty in più di 100 Congressi Nazionali e Internazionali

Abilità organizzative

Organizzazione e coordinamento di gruppi di lavoro e studi clinici collaborativi nazionali e internazionali.
Coordinamento delle linee guida nazionali e internazionali.

Competenze informatiche

Microsoft Windows, Office e gestione di banche dati elettroniche.

INFORMAZIONI AGGIUNTIVE

Premi

2019: Pfizer research grant INNOVARE su "Lipid profiles in patients with ulcerative colitis treated with tofacitinib profile: understanding the mechanism of action." Euro 50,000
2017 ECCO Vifor Grant su "Efficacy of iron supplementation in patients with inflammatory bowel disease and chronic fatigue" - Euro 40,000
2014: Best abstract, Digital Oral Poster Presentation, Session 4, ECCO Congress, Copenhagen (DK)

Certificazioni

10 04 2017-10 04 2023: Abilitazione Scientifica Nazionale a Professore Associato in Gastroenterologia - MIUR – Italia

Progetti principali

2021-2026: Coordinatore del progetto ECCO E-QUALITY sugli standard di cura nelle IBD
2020-2021: Membro del Consensus Panel nelle linee guida ECCO su Gravidanza e Allattamento nelle IBD
2020-2021: Leader del gruppo di lavoro nelle linee guida ECCO su tumori maligni e IBD
2019-2021: Membro del Consensus Panel sulle linee guida ECCO basate su GRADE sulla terapia nella colite ulcerosa
2019-in corso: Membro del Consensus Panel sulle linee guida IG-IBD basate su GRADE sulla terapia biologica nelle malattie infiammatorie intestinali
2018-2020: Coordinatore del progetto ECCO: "Quality of Standards of Care in IBD"
2018-in corso: Coordinatore del Registro Nazionale sui Biosimilari nelle IBD per conto del Gruppo Italiano per le IBD (IG-IBD)
Ottobre 2017-2020: Coordinatore delle Linee guida ECCO basate su GRADE sulla terapia nella malattia di Crohn
Marzo 2017-in corso: e-Guide Champion per l'ECCO
<http://www.e-guide.ecco-ibd.eu/about-us2017-2021>
Principal Investigator nel trial randomizzato controllato multicentrico europeo A *Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic Crohn's disease recurrence* EUDRACT 2017-002258-36
Ottobre 2016-Ottobre 2017: Working Group leader per l'ECCO "Diagnostic and Monitoring Consensus"
2014 - Bibliographic Fellow per la International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) Progetto STRIDE (Selezione di bersagli terapeutici nelle malattie infiammatorie intestinali)
2010 - Principal investigator nello studio di validazione dell'indice di gravità endoscopica della colite ulcerosa (UCEIS)
2008-in corso Sub-investigatore in più di 150 studi clinici randomizzati multicentrici di fase 1-4 sulle malattie infiammatorie intestinali

Memberships

Agosto 2018-attuale: Associate Editor del Journal of Crohn's and Colitis (JCC)
Gennaio 2018-in corso: Chair del Comitato Scientifico del Gruppo Italiano di Malattie Infiammatorie Intestinali (IG-IBD)
Ottobre 2016-Marzo 2019: Membro ECCO CONFER
Febbraio 2015-Febbraio 2018: Membro del Comitato delle Linee guida (GuiCom) della European Crohn's Colitis Organisation (ECCO)
Febbraio 2015-luglio 2018: Membro dell'Editorial Board del Journal of Crohn's and Colitis (JCC)
Gennaio 2014-gennaio 2017: Membro del Comitato Scientifico del Gruppo Italiano Malattie Infiammatorie Intestinali (IG-IBD)
3 aprile 2014: Membro del Consensus IO-IBD "Treat to Target"
Giugno 2010: Membro della WHO Consensus Conference su "ICF Core Sets for IBD" – Nottwil (CH)
Ottobre 2006 - Marzo 2009 Presidente della Young European Crohn's Colitis Organization (Y-ECCO)
2006-oggi: Membro dell'European Crohn's Colitis Organisation (ECCO)

2006-in corso: Membro del Gruppo Italiano - Malattie Infiammatorie Intestinali (IG-IBD)

2005-2009: Membro della Società Italiana di Gastroenterologia ed Endoscopia Digestiva (SIGE)

19 luglio 2012-in corso: Licenza Medica - OMCEO Milano n. 42409

30 marzo 2005-19 luglio 2012: Licenza Medica - OMceO Bari n. 12903

H-Index

43
(Scopus, 30/09/2021)

Pubblicazioni

1. Privitera G, Onali S, Pugliese D, et al. Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. *J Crohn's Colitis* 2021; 15: 335–339.
2. Spinelli A, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. *J Crohn's Colitis*. Epub ahead of print 12 October 2021. DOI: 10.1093/ECCO-JCC/JJAB177.
3. Fiorino G, Bonovas S, Gilardi D, et al. Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study among General Practitioners. *J Crohn's Colitis* 2021; 14: 1777–1779.
4. Raine T, Bonovas S, Burisch J, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. *J Crohn's Colitis*. Epub ahead of print 12 October 2021. DOI: 10.1093/ECCO-JCC/JJAB178.
5. Fiorino G, Danese S, Giacobazzi G, et al. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. *Dig Liver Dis* 2021; 53: 403–408.
6. Ribaldone DG, Imperatore N, Le Grazie M, et al. Inflammatory bowel disease course in liver transplant versus non-liver transplant patients for primary sclerosing cholangitis: LIVIBD, an IG-IBD study. *Dig Liver Dis* 2021; 53: 712–716.
7. Allocca M, Craviotto V, Bonovas S, et al. Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. *Clin Gastroenterol Hepatol*. Epub ahead of print 22 April 2021. DOI: 10.1016/j.cgh.2021.04.029.
8. Allocca M, Furfaro F, Fiorino G, et al. Point-of-care ultrasound in inflammatory bowel disease. Oxford University Press, 2021.
9. Furfaro F, Alfarone L, Gilardi D, et al. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease. *Curr Drug Targets* 2021; 22: 760–769.
10. Viola A, Fiorino G, Costantino G, et al. Epidemiology and clinical course of late onset inflammatory bowel disease. *Minerva Gastroenterol*. Epub ahead of print 31 05 2021. DOI: 10.23736/s2724-5985.21.02890-4.
11. Adamina M, Fiorino G. At the Crossroads of Caution and Intervention: Anti-TNF Therapy Prior to Elective CD Surgery. *J Crohn's Colitis* 2021; 15: 1778–1779.
12. Craviotto V, Furfaro F, Loy L, et al. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. Baishideng Publishing Group Co, 2021.
13. Spagnuolo R, Corea A, Napolitano D, et al. Nursing-sensitive outcomes in adult inflammatory bowel disease: A systematic review. Blackwell Publishing Ltd, 2021.
14. Fiorino G, Allocca M, Danese S. Adalimumab biosimilar in inflammatory bowel disease. *Lancet Gastroenterol Hepatol* 2021; 6: 775–776.
15. Napolitano D, Scaldaferrri F, Fiorino G, et al. Knowledge of Diagnostic and

Therapeutic Aspects of IBD among Nurses Working in Digestive Endoscopy: A Nationwide Italian Survey. *Gastroenterol Nurs* 2021; 44: E59–E66.

16. Solitano V, D'Amico F, Allocca M, et al. Rediscovering histology: what is new in endoscopy for inflammatory bowel disease? *Therap Adv Gastroenterol*; 14. Epub ahead of print 2021. DOI: 10.1177/17562848211005692.
17. Noviello D, Mager R, Roda G, et al. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. *Front Immunol*; 12. Epub ahead of print 17 05 2021. DOI: 10.3389/fimmu.2021.611256.
18. Mazza S, Piazza O, Sed N, Conforti FS, et al. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. *Clin Transl Sci* 2021; 00: 1–10.
19. Fiorino G, Estevinho MM, Lopes DJM, et al. Inflammatory Bowel Disease in Migrant Populations: Should we look Even Further Back? *Curr Drug Targets* 2021; 22: 1706–1715.
20. Fiorino G, Danese S. The new frontier: Certifying quality standards in the inflammatory bowel disease care. John Wiley and Sons Inc, 2021.
21. Solitano V, Fiorino G, D'Amico F, et al. Thrombosis in IBD in the Era of JAK Inhibition. *Curr Drug Targets* 2021; 22: 126–136.
22. Allocca M, Filippi E, Costantino A, et al. Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation. *United Eur Gastroenterol J* 2021; 9: 438–442.
23. Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. *J Crohn's Colitis*; 14. Epub ahead of print 2020. DOI: 10.1093/ecco-jcc/jjz187.
24. Fiorino G, Allocca M, Furfaro F, et al. Inflammatory bowel disease care in the COVID-19 pandemic era: the Humanitas, Milan experience. *J Crohn's & colitis*. Epub ahead of print 2020. DOI: 10.1093/ecco-jcc/jjaa058.
25. Solitano V, D'amico F, Fiorino G, et al. Key strategies to optimize outcomes in mild-to-moderate ulcerative colitis. *J Clin Med* 2020; 9: 1–19.
26. D'Amico F, Peyrin-Biroulet L, Danese S, et al. New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming? *Curr Opin Pharmacol* 2020; 55: 141–150.
27. Solitano V, D'Amico F, Fiorino G, et al. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. *Expert Rev Clin Immunol* 2020; 16: 1019–1028.
28. Allocca M, Chaparro M, Gonzalez HA, et al. Patients with inflammatory bowel disease are not at increased risk of covid-19: A large multinational cohort study. *J Clin Med* 2020; 9: 1–10.
29. Fiorino G, Lytras T, Younge L, et al. Quality of care standards in inflammatory bowel diseases: A European Crohn's and colitis organisation [ECCO] position paper. *J Crohn's Colitis* 2020; 14: 1037–1048.
30. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment. *J Crohn's Colitis* 2020; 14: 4–22.
31. Fiorino G, Allocca M, Furfaro F, et al. Inflammatory bowel disease care in the COVID-19 pandemic era: The humanitas, milan, experience. *J Crohn's Colitis* 2020; 14: 1330–1333.
32. Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. *J Crohn's Colitis* 2020; 14: 155–168.

33. Torres J, Bonovas S, Fiorino G. Proactive TDM for crohn's disease patients in clinical remission under anti-TNF treatment: Current state of evidence. *J Crohn's Colitis* 2020; 14: 1338–1339.
34. Tlais AZA, Fiorino GM, Polo A, et al. High-value compounds in fruit, vegetable and cereal byproducts: An overview of potential sustainable reuse and exploitation. *Molecules*; 25. Epub ahead of print 1 July 2020. DOI: 10.3390/MOLECULES25132987.
35. Lippolis V, de Angelis E, Fiorino GM, et al. Geographical origin discrimination of monofloral honeys by direct analysis in real time ionization-high resolution mass spectrometry (DART-HRMS). *Foods*; 9. Epub ahead of print 1 September 2020. DOI: 10.3390/FOODS9091205.
36. Loy L, Fiorino G, Roda G, et al. New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases. *Curr Drug Targets* 2020; 22: 370–378.
37. Gabbiadini R, Zacharopoulou E, Furfaro F, et al. Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality? *Curr Drug Targets* 2020; 22: 347–355.
38. Fiorino G, Gilardi D, Radice S, et al. Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. *Am J Gastroenterol* 2020; 115: 1719–1721.
39. Fiorino G, Allocca M, Correale C, et al. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. *Expert Opin Biol Ther* 2020; 20: 421–427.
40. Fiorino G, Bonifacio C, Allocca M, et al. Impact of therapies on bowel damage in Crohn's disease. *United Eur Gastroenterol J* 2020; 8: 410–417.
41. D'Amico F, Pouillon L, Argollo M, et al. Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. *Dig Liver Dis* 2020; 52: 138–142.
42. Furfaro F, Vuitton L, Fiorino G, et al. SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. *Nat Rev Gastroenterol Hepatol* 2020; 17: 507–516.
43. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: An IG-IBD study. *Gut* 2020; 69: 1213–1217.
44. Allocca M, Fiorino G, Zallot C, et al. Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. *Clin Gastroenterol Hepatol* 2020; 18: 2134–2135.
45. Danese S, Fiorino G, Peyrin-Biroulet L. Positioning Therapies in Ulcerative Colitis. *Clin Gastroenterol Hepatol* 2020; 18: 1280-1290.e1.
46. Lenti MVMV, Armuzzi A, Castiglione F, et al. Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. *Dig Liver Dis* 2020; 52: 44–50.
47. Allocca M, Fiorino G, Furfaro F, et al. Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. *Clin Gastroenterol Hepatol* 2020; 18: 1882–1883.
48. Gadaleta RMRM, Garcia-Irigoyen O, Cariello M, et al. Corrigendum to 'Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid x receptor': [EBioMedicine 54 (2020) 102719] (EBioMedicine (2020) 54, (S2352396420300943), (10.1016/j.ebiom.2020.102719)). *EBioMedicine*; 57.
49. Fiorino G, Peyrin-Biroulet L, Danese S. Protecting patients with IBD during the COVID-19 pandemic. *Lancet Gastroenterol Hepatol* 2020; 5: 639.

50. Eliadou E, Moleiro J, Ribaldone DGDG, et al. Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. *J Crohn's Colitis* 2020; 14: 480–489.
51. Gadaleta RMRM, Garcia-Irigoyen O, Cariello M, et al. Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor. *EBioMedicine*; 54.
52. Allocca M, Guidelli GMGM, Borroni RGRG, et al. Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. *Pharmacol Res*; 160.
53. Zacharopoulou E, Craviotto V, Fiorino G, et al. Targeting the gut layers in Crohn's disease: mucosal or transmural healing? *Expert Rev Gastroenterol Hepatol* 2020; 14: 775–787.
54. D'Amico F, Fiorino G, Furfaro F, et al. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. *Expert Rev Gastroenterol Hepatol* 2020; 14: 765–773.
55. Gilardi D, Gabbiadini R, Allocca M, et al. PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD. *Expert Rev Gastroenterol Hepatol* 2020; 797–806.
56. Fiorino G, Colombo M, Natale C, et al. Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. *Ann Intern Med* 2020; 173: 405–407.
57. Zilli A, Capogreco A, Furfaro F, et al. Improving quality of care in endoscopy of inflammatory bowel disease: can we do better? *Expert Rev Gastroenterol Hepatol* 2020; 14: 819–828.
58. Saibeni S, Scucchi L, Dragoni G, et al. Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. *United Eur Gastroenterol J* 2020; 8: 1228–1235.
59. Vespa E, Furfaro F, Allocca M, et al. Endoscopy after surgery in inflammatory bowel disease: Crohn's disease recurrence and pouch surveillance. *Expert Rev Gastroenterol Hepatol* 2020; 14: 829–841.
60. Carvello M, Di Candido F, Greco M, et al. The trend of C-Reactive protein allows a safe early discharge after surgery for Crohn's disease. *Updates Surg* 2020; 72: 985–989.
61. Fantini MCMC, Biancone L, Dragoni G, et al. Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. 2020; 26: E134–E136.
62. Ellul P, Zammit SC, Katsanos KH, et al. Corrigendum: Perception of reproductive health in women with inflammatory bowel disease (Journal of Crohn's and Colitis DOI: 10.1093/ecco-jcc/jjw011). *J Crohn's Colitis*; 13. Epub ahead of print 2019. DOI: 10.1093/ecco-jcc/jjy221.
63. Bonifacio C, Gennaro N, Fiorino G. *Role of imaging in detecting bowel fibrosis and bowel damage*. 2019.
64. Danese S, Fiorino G. Anti-TNF biosimilars in inflammatory bowel disease: Searching the proper patient's profile. *Curr Med Chem*; 26. Epub ahead of print 2019. DOI: 10.2174/0929867325666180514100204.
65. Costantino C, Mazzucco W, Marotta C, et al. Methodological issues in a cross-sectional survey on cervical cancer screening using telephone interviews in Sicily (Italy): a SWOT analysis. *J Int Med Res* 2019; 47: 5174–5184.
66. Fiorino G, Sturniolo GC, Bossa F, et al. A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-

- Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis. *Cells* 2019; 8: 523.
67. Fiorino GM, Fresch M, Brömmer I, et al. Mass spectrometry-based untargeted proteomics for the assessment of food authenticity: The case of farmed versus wild-Type salmon. *J AOAC Int* 2019; 102: 1339–1345.
 68. Ellul P, Zammit SC, Katsanos KH, et al. Corrigendum: Perception of reproductive health in women with inflammatory bowel disease (Journal of Crohn's and Colitis DOI: 10.1093/ecco-jcc/jjw011). *J Crohn's Colitis* 2019; 13: 815.
 69. Fiorino GM, Losito I, De Angelis E, et al. Assessing fish authenticity by direct analysis in real time-high resolution mass spectrometry and multivariate analysis: discrimination between wild-type and farmed salmon. *Food Res Int* 2019; 116: 1258–1265.
 70. Sammarco G, Shalaby M, Elangovan S, et al. Hyaluronan Accelerates Intestinal Mucosal Healing through Interaction with TSG-6. *Cells*; 8.
 71. Roda G, Porru E, Katsanos K, et al. Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. *Cells*; 8.
 72. Fiorino G, Gilardi D, Correale C, et al. Biosimilars of adalimumab: the upcoming challenge in IBD. *Expert Opin Biol Ther* 2019; 19: 1023–1030.
 73. Argollo M, Gilardi D, Roda G, et al. Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time? *Curr Pharm Des* 2019; 25: 47–56.
 74. Argollo M, Fiorino G, Gilardi D, et al. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? *Curr Pharm Des* 2019; 25: 7–12.
 75. Sturm A, Maaser C, Calabrese E, et al. Ecco-esgar guideline for diagnostic assessment in ibd part 2: Ibd scores and general principles and technical aspects. *J Crohn's Colitis* 2019; 13: 273-284E.
 76. Pugliese D, Daperno M, Fiorino G, et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. *Dig Liver Dis* 2019; 51: 972–977.
 77. Maaser C, Sturm A, Vavricka SRSR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. *J Crohn's Colitis* 2019; 13: 144–164.
 78. Leone D, Gilardi D, Corrà BEBE, et al. Psychological Functioning of Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2019; 25: E112.
 79. Loy L, Roda G, Fiorino G, et al. Detection and management of early stage inflammatory bowel disease: an update for clinicians. *Expert Rev Gastroenterol Hepatol* 2019; 13: 547–555.
 80. Viola A, Monterubbianesi R, Scalisi G, et al. Late-onset Crohn's disease: A comparison of disease behaviour and therapy with younger adult patients: The Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. *Eur J Gastroenterol Hepatol* 2019; 31: 1361–1369.
 81. Fiorino G, Allocca M, Chaparro M, et al. 'Quality of care' standards in inflammatory bowel disease: A systematic review. *J Crohn's Colitis* 2019; 13: 127–137.
 82. Pouillon L, Danese S, Hart A, et al. Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. *Aliment Pharmacol Ther* 2019; 49: 1181–1187.
 83. Viola A, Pugliese D, Renna S, et al. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective

study. *Dig Liver Dis* 2019; 51: 510–515.

84. Leone D, Gilardi D, Corrà BEBE, et al. Psychological characteristics of inflammatory bowel disease patients: A comparison between active and nonactive patients. *Inflamm Bowel Dis* 2019; 25: 1399–1407.
85. Armuzzi A, Fiorino G, Variola A, et al. The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy. *Inflamm Bowel Dis* 2019; 25: 568–579.
86. Beeg M, Nobili A, Orsini B, et al. A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. *Sci Rep*; 9.
87. D'Amico F, Fiorino G, Peyrin-Biroulet L, et al. Vedolizumab for the treatment of inflammatory bowel diseases: From symptomatic control to mucosal healing. *Immunotherapy* 2019; 11: 565–575.
88. Iacucci M, Cannatelli R, Tontini GEGE, et al. Improving the quality of surveillance colonoscopy in inflammatory bowel disease. *Lancet Gastroenterol Hepatol* 2019; 4: 971–983.
89. Allocca M, Fiorino G, Bonifacio C, et al. Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. *Clin Gastroenterol Hepatol* 2019; 17: 2397–2415.
90. Fiorino G, Peyrin-Biroulet L, Danese S. Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. *Gastroenterology* 2019; 156: 2349–2351.
91. Vegni E, Gilardi D, Bonovas S, et al. Illness Perception in Inflammatory Bowel Disease Patients is Different between Patients with Active Disease or in Remission: A Prospective Cohort Study. *J Crohn's Colitis* 2019; 13: 417–423.
92. D'Amico F, Parigi TLTL, Fiorino G, et al. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. *Therap Adv Gastroenterol*; 12. Epub ahead of print 4 05 2019. DOI: 10.1177/1756284819848631.
93. Danese S, Hart A, Dignass A, et al. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment® MMX®) for active, mild-to-moderate ulcerative colitis. *United Eur Gastroenterol J* 2019; 7: 1171–1182.
94. Fiorino G, Caprioli F, Daperno M, et al. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis* 2019; 51: 632–639.
95. Candido F Di, Fiorino G, Spadaccini M, et al. Are Surgical Rates Decreasing in the Biological Era In IBD? *Curr Drug Targets* 2019; 20: 1356–1362.
96. Šimurina M, de Haan N, Vučković F, et al. Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. *Gastroenterology*; 154. Epub ahead of print 2018. DOI: 10.1053/j.gastro.2018.01.002.
97. Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNF α drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study. *Am J Gastroenterol*; 113. Epub ahead of print 2018. DOI: 10.1038/ajg.2017.501.
98. Danese S, Bonovas S, Lopez A, et al. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. *Gastroenterology*; 155. Epub ahead of print 2018. DOI: 10.1053/j.gastro.2018.03.032.
99. Fiorino G, Ruiz-Arguello MB, Maguregui A, et al. Full interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. *Inflamm Bowel*

- Dis*; 24. Epub ahead of print 2018. DOI: 10.1093/ibd/izx086.
100. Bonovas S, Nikolopoulos GK, Lytras T, et al. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. *Br J Clin Pharmacol*; 84. Epub ahead of print 2018. DOI: 10.1111/bcp.13456.
 101. Allocca M, Gilardi D, Fiorino G, et al. Sexual and reproductive issues and inflammatory bowel disease: A neglected topic in men. *Eur J Gastroenterol Hepatol*; 30. Epub ahead of print 2018. DOI: 10.1097/MEG.0000000000001074.
 102. Argollo M, Fiorino G, Peyrin-Biroulet L, et al. Vedolizumab for the treatment of Crohn's disease. *Expert Rev Clin Immunol*; 14. Epub ahead of print 2018. DOI: 10.1080/1744666X.2018.1438189.
 103. Menichetti J, Fiorino G, Vegni E. Personalizing psychological treatment along the IBD journey: From diagnosis to surgery. *Curr Drug Targets*; 19. Epub ahead of print 2018. DOI: 10.2174/1389450118666170502142939.
 104. Fiorino GM, Losito I, De Angelis E, et al. Direct analysis in real time coupled to high resolution mass spectrometry as a rapid tool to assess salmon (*Salmo salar*) freshness. *J Mass Spectrom* 2018; 53: 781–791.
 105. Goncalves J, Santos M, Acurcio R, et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. *Aliment Pharmacol Ther* 2018; 48: 507–522.
 106. Allocca M, Fiorino G, Bonifacio C, et al. Comparative accuracy of bowel ultrasound versus magnetic resonance enterography in combination with colonoscopy in assessing Crohn's disease and guiding clinical decision-making. *J Crohn's Colitis* 2018; 12: 1280–1287.
 107. D'Amico F, Fiorino G, Furfaro F, et al. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. *Expert Opin Investig Drugs* 2018; 27: 595–599.
 108. Sebastian S, Black C, Pugliese D, et al. The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. *Aliment Pharmacol Ther* 2018; 48: 941–950.
 109. Allocca M, Fiorino G, Bonovas S, et al. Accuracy of humanitas ultrasound criteria in assessing disease activity and severity in ulcerative colitis: A prospective study. *J Crohn's Colitis* 2018; 12: 1385–1391.
 110. Allocca M, Gilardi D, Fiorino G, et al. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. *Expert Opin Investig Drugs* 2018; 27: 623–629.
 111. Kopylov U, Verstockt B, Biedermann L, et al. Effectiveness and safety of vedolizumab in anti-TNF-naïve patients with inflammatory bowel disease—a multicenter retrospective European study. *Inflamm Bowel Dis* 2018; 24: 2442–2451.
 112. Fiorino G, D'Amico F, Italia A, et al. JAK inhibitors: Novel developments in management of ulcerative colitis. *Best Pract Res Clin Gastroenterol* 2018; 32–33: 89–93.
 113. Allocca M, Furfaro F, Fiorino G, et al. Can IL-23 be a good target for ulcerative colitis? *Best Pract Res Clin Gastroenterol* 2018; 32–33: 95–102.
 114. Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. *Inflamm Bowel Dis*; 23. Epub ahead of print 2017. DOI: 10.1097/MIB.0000000000000995.
 115. Aratari A, Bossa F, Cappello M, et al. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis*; 49. Epub ahead of print

2017. DOI: 10.1016/j.dld.2017.01.141.
116. Lindsay JO, Irving PM, Mantzaris GJ, et al. ECCO IBD curriculum. *J Crohn's Colitis*; 11. Epub ahead of print 2017. DOI: 10.1093/ecco-jcc/jjx004.
 117. Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: Diagnosis and medical management. *J Crohn's Colitis*; 11. Epub ahead of print 2017. DOI: 10.1093/ecco-jcc/jjw168.
 118. Fries W, Viola A, Manetti N, et al. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study". *Dig Liver Dis*; 49. Epub ahead of print 2017. DOI: 10.1016/j.dld.2016.09.006.
 119. Ungaro F, Tacconi C, Massimino L, et al. MFS2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. *Gastroenterology*; 153. Epub ahead of print 2017. DOI: 10.1053/j.gastro.2017.07.048.
 120. Sigall-Boneh R, Levine A, Lomer M, et al. Research gaps in diet and nutrition in inflammatory bowel disease. A topical review by D-ECCO working group [Dietitians of ECCO]. *J Crohn's Colitis*; 11. Epub ahead of print 2017. DOI: 10.1093/ecco-jcc/jjx109.
 121. Danese S, Fiorino G, Raine T, et al. ECCO Position statement on the use of biosimilars for inflammatory bowel disease-an update. *J Crohn's Colitis*; 11. Epub ahead of print 2017. DOI: 10.1093/ecco-jcc/jjw198.
 122. Fiorino G, Correale C, Radice S, et al. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients. *Aliment Pharmacol Ther*; 46. Epub ahead of print 2017. DOI: 10.1111/apt.14262.
 123. Allocca M, Landi R, Bonovas S, et al. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. *Digestion*; 96. Epub ahead of print 2017. DOI: 10.1159/000480231.
 124. Fiorino G, Morin M, Bonovas S, et al. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. *J Crohn's & colitis*; 11. Epub ahead of print 2017. DOI: 10.1093/ecco-jcc/jjw185.
 125. Allocca M, Bonifacio C, Fiorino G, et al. Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. *Dig Liver Dis*; 49. Epub ahead of print 2017. DOI: 10.1016/j.dld.2017.03.012.
 126. Katsanos KH, Domènech E, Rahier J-F, et al. Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics. *J Crohn's & colitis*; 11. Epub ahead of print 2017. DOI: 10.1093/ecco-jcc/jjw131.
 127. Fiorino G, Bonovas S, Cicerone C, et al. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. *Expert Opin Drug Saf*; 16. Epub ahead of print 2017. DOI: 10.1080/14740338.2017.1298743.
 128. Furfaro F, Gilardi D, Allocca M, et al. IL-23 Blockade for Crohn's disease: next generation of anti-cytokine therapy. *Expert Rev Clin Immunol*; 13. Epub ahead of print 2017. DOI: 10.1080/1744666X.2017.1279055.
 129. Gilardi D, Fiorino G, Furfaro F, et al. Comparison of two methods for the in-vivo diagnosis of *Helicobacter pylori* infection using a tablet of ¹³C-urea. *Minerva Gastroenterol Dietol*; 63. Epub ahead of print 2017. DOI: 10.23736/S1121-421X.17.02411-4.
 130. Bonovas S, Fiorino G, Lytras T, et al. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. *Aliment Pharmacol Ther*; 45. Epub ahead of print

2017. DOI: 10.1111/apt.14023.

131. Bonovas S, Fiorino G, Lytras T, et al. Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer—authors' reply. *Aliment Pharmacol Ther*; 45. Epub ahead of print 2017. DOI: 10.1111/apt.14084.
132. Argollo M, Fiorino G, Hindryckx P, et al. Novel therapeutic targets for inflammatory bowel disease. *Journal of Autoimmunity* 2017; 85: 103–116.
133. Danese S, Fiorino G, Peyrin-Biroulet L. Filgotinib in Crohn's Disease: JAK Is Back. *Gastroenterology*; 153. Epub ahead of print 2017. DOI: 10.1053/j.gastro.2017.06.040.
134. Allocca M, Fiorino G, Danese S. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? *Dig Dis Sci*; 62. Epub ahead of print 2017. DOI: 10.1007/s10620-017-4693-9.
135. Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: Towards disease modification trials. *Gut*; 66. Epub ahead of print 2017. DOI: 10.1136/gutjnl-2017-314519.
136. Avila-Ribeiro P, Fiorino G, Danese S. The experience with biosimilars of infliximab in inflammatory bowel disease. *Curr Pharm Des*; 23. Epub ahead of print 2017. DOI: 10.2174/1381612824666171204095342.
137. Allocca M, Fiorino G, Gilardi D, et al. Biologic therapies in ulcerative colitis: primi inter pares? *Curr Drug Targets* 2016; 17: 1–1.
138. Ventham NT, Kennedy NA, Adams AT, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation O5 mediate genetic risk in inflammatory bowel disease. *Nat Commun*; 7. Epub ahead of print 2016. DOI: 10.1038/ncomms13507.
139. Fiorino G, Cortes PN, Ellul P, et al. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. *Clin Gastroenterol Hepatol* 2016; 14: 1426-1432.e1.
140. Kopylov U, Katsanos KH, Van Der Woude CJ, et al. European experience with methotrexate treatment in Crohn's disease: A multicenter retrospective analysis. *Eur J Gastroenterol Hepatol* 2016; 28: 802–806.
141. López-Posadas R, Becker C, Günther C, et al. Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. *J Clin Invest* 2016; 126: 611–626.
142. Armuzzi A, Gionchetti P, Daperno M, et al. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. *Digestive and Liver Disease* 2016; 48: 360–370.
143. Armuzzi A, Gionchetti P, Daperno M, et al. Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370)). *Digestive and Liver Disease* 2016; 48: 1103.
144. Ellul P, Zammita SC, Katsanos KH, et al. Perception of reproductive health in women with inflammatory bowel disease. *J Crohn's Colitis* 2016; 10: 886–891.
145. Vuitton L, Marteau P, Sandborn WJ, et al. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. *Gut* 2016; 65: 1447–1455.
146. Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials. *Medicine (United States)*; 95. Epub ahead of print 2016. DOI: 10.1097/MD.0000000000002308.

147. Bonovas S, Fiorino G, Allocca M, et al. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. *Clin Gastroenterol Hepatol* 2016; 14: 1385-1397.e10.
148. Furfaro F, Fiorino G, Allocca M, et al. Emerging therapeutic targets and strategies in Crohn's disease. *Expert Review of Gastroenterology and Hepatology* 2016; 10: 735-744.
149. Bonovas S, Fiorino G, Lytras T, et al. Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials. *World Journal of Gastroenterology* 2016; 22: 4594-4603.
150. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Preventing collateral damage in Crohn's disease: The Lémann index. *J Crohn's Colitis* 2016; 10: 495-500.
151. Fiorino G, Fazio M, Danese S. Biosimilar therapies in inflammatory bowel disease: Should we care about patient profile? *Expert Review of Clinical Immunology* 2016; 12: 361-363.
152. Fiorino G, Gilardi D, Danese S. The clinical potential of etrolizumab in ulcerative colitis: Hypes and hopes. *Therapeutic Advances in Gastroenterology* 2016; 9: 503-512.
153. Danese S, Fiorino G, Michetti P. Changes in biosimilar knowledge among European Crohn's Colitis Organization [ECCO] members: An updated survey. *J Crohn's Colitis* 2016; 10: 1362-1365.
154. Fiorino G, Danese S. Adalimumab and azathioprine combination therapy for Crohn's disease: A shining diamond? *Journal of Crohn's and Colitis* 2016; 10: 1257-1258.
155. Fernandes C, Allocca M, Danese S, et al. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. *Immunotherapy* 2015; 7: 175-190.
156. Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: Inflammatory bowel disease and malignancies. *J Crohn's Colitis* 2015; 9: 945-965.
157. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. *J Crohn's Colitis* 2015; 9: 107-124.
158. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol* 2015; 110: 1324-1338.
159. Pariente B, Mary JY, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. *Gastroenterology* 2015; 148: 52-63.e3.
160. Fiorino G, Bonifacio C, Allocca M, et al. Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease. *J Crohn's Colitis* 2015; 9: 633-639.
161. Quetglas EG, Armuzzi A, Wigge S, et al. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. *European Journal of Clinical Pharmacology* 2015; 71: 773-799.
162. Gilardi D, Fiorino G, Allocca M, et al. Golimumab: Clinical update on its use for ulcerative colitis. *Drugs of Today* 2015; 51: 171-184.
163. Moja L, Danese S, Fiorino G, et al. Systematic review with network meta-analysis: Comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease. *Alimentary Pharmacology and Therapeutics*

- 2015; 41: 1055–1065.
164. Bravatà I, Allocca M, Fiorino G, et al. Integrins and adhesion molecules as targets to treat inflammatory bowel disease. *Current Opinion in Pharmacology* 2015; 25: 67–71.
 165. Nuti F, Fiorino G, Danese S. Adalimumab for the treatment of pediatric Crohns disease. *Expert Rev Clin Immunol* 2015; 11: 963–972.
 166. Danese S, Peyrin-Biroulet L, Fiorino G. Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: Which is the crystal ball? *Gut* 2015; 64: 1347–1348.
 167. Fiorino G, Allocca M, Danese S. Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? *Clinical Gastroenterology and Hepatology* 2015; 13: 1767–1769.
 168. Danese S, Fiorino G, Peyrin-Biroulet L. Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way? *Gastroenterology* 2015; 149: 1121–1123.
 169. Fiorino G, Omodei PD. Psoriasis and Inflammatory Bowel Disease: Two Sides of the Same Coin? *Journal of Crohn's & colitis* 2015; 9: 697–698.
 170. Annese V, Vecchi M, Bossa F, et al. Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. *Dig Liver Dis* 2014; 46: 963–968.
 171. Armuzzi A, Pugliese D, Danese S, et al. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. *Inflamm Bowel Dis* 2014; 20: 1368–1374.
 172. Cesarini M, Katsanos K, Papamichael K, et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study. *Dig Liver Dis* 2014; 46: 135–139.
 173. Spinelli A, Fiorino G, Bazzi P, et al. Preoperative Magnetic Resonance Enterography in Predicting Findings and Optimizing Surgical Approach in Crohn's Disease. *J Gastrointest Surg* 2014; 18: 83–91.
 174. Danese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for moderately to severely active ulcerative colitis. *Annals of Internal Medicine* 2014; 160: 704–711.
 175. Fiorino G, Girolomoni G, Lapadula G, et al. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDEmaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. *Autoimmunity Reviews* 2014; 13: 751–755.
 176. Allocca M, Fiorino G, Vermeire S, et al. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: Importance of specificity of endothelial target. *Expert Review of Clinical Immunology* 2014; 10: 885–895.
 177. Fiorino G, Gilardi D, Naccarato P, et al. Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. *Dig Liver Dis* 2014; 46: 330–334.
 178. Gilardi D, Fiorino G, Genua M, et al. Complementary and alternative medicine in inflammatory bowel diseases: What is the future in the field of herbal medicine? *Expert Review of Gastroenterology and Hepatology* 2014; 8: 835–846.
 179. Bravatà I, Fiorino G, Allocca M, et al. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease. *Scandinavian Journal of Gastroenterology* 2014; 50: 113–120.
 180. Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated

- inflammation in inflammatory bowel disease patients receiving anti-TNF- α agents. *Autoimmun Rev* 2014; 13: 15–19.
181. Danese S, Fiorino G, Fernandes C, et al. Catching the Therapeutic Window of Opportunity in Early Crohn's Disease. *Curr Drug Targets* 2014; 15: 1056–1063.
 182. Leone D, Menichetti J, Fiorino G, et al. State of the Art: Psychotherapeutic Interventions Targeting the Psychological Factors Involved in IBD. *Curr Drug Targets* 2014; 15: 1020–1029.
 183. Fiorino G, Allocca M, Danese S. Commentary: Anaemia in inflammatory bowel disease - The most common and ignored extra intestinal manifestation. *Alimentary Pharmacology and Therapeutics* 2014; 39: 227–228.
 184. Allocca M, Fiorino G, Danese S. Iron Deficiency: The Hidden Miscreant in Inflammatory Bowel Disease. *Curr Drug Targets* 2014; 15: 1011–1019.
 185. Danese S, Fiorino G, Michetti P. Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. *J Crohn's Colitis* 2014; 8: 1548–1550.
 186. Fiorino G, Danese S. Commentary: Adjunct antibiotic combination therapy for ulcerative colitis - Is it time to investigate *Fusobacterium varium*? *Alimentary Pharmacology and Therapeutics* 2014; 39: 1333.
 187. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: The right way? *Best Practice and Research: Clinical Gastroenterology* 2014; 28: 465–471.
 188. Fiorino G, Danese S. Etrolizumab in ulcerative colitis: Tightening leukocyte traffic control in the inflamed mucosa: Comment. *Gastroenterology* 2014; 147: 1433–1435.
 189. Cammarota T, Ribaldone DG, Resegotti A, et al. Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease. *Scand J Gastroenterol*; 48. Epub ahead of print 2013. DOI: 10.3109/00365521.2013.777774.
 190. Armuzzi A, Pugliese D, Danese S, et al. Infliximab in steroid-dependent ulcerative colitis: Effectiveness and predictors of clinical and endoscopic remission. *Inflamm Bowel Dis* 2013; 19: 1065–1072.
 191. Iborra M, Bernuzzi F, Correale C, et al. Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease. *Clin Exp Immunol* 2013; 173: 250–258.
 192. Fiorino G, Bonifacio C, Padrenostro M, et al. Comparison between 1.5 and 3.0 tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic crohn's disease. *Dig Dis Sci* 2013; 58: 3246–3255.
 193. Spinelli A, Bazzi P, Sacchi M, et al. Short-Term Outcomes of Laparoscopy Combined with Enhanced Recovery Pathway after Ileocecal Resection for Crohn's Disease: A Case-Matched Analysis. *J Gastrointest Surg*; 17. Epub ahead of print 2013. DOI: 10.1007/s11605-012-2012-5.
 194. Indriolo A, Fagiuoli S, Pasulo L, et al. Letter: Infliximab therapy in inflammatory bowel disease patients after liver transplantation. *Alimentary Pharmacology and Therapeutics* 2013; 37: 840–842.
 195. Allocca M, Jovani M, Fiorino G, et al. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target. *Curr Drug Targets*; 14. Epub ahead of print 2013. DOI: 10.2174/13894501113146660224.
 196. Peyrin-Biroulet L, Fiorino G, Buisson A, et al. First-line therapy in adult Crohn's disease: Who should receive anti-TNF agents? *Nat Rev Gastroenterol Hepatol*; 10. Epub ahead of print 2013. DOI: 10.1038/nrgastro.2013.31.

197. Jovani M, Fiorino G, Danese S. Commentary: Associations between immune activation, intestinal permeability and irritable bowel syndrome. *Aliment Pharmacol Ther*; 37. Epub ahead of print 2013. DOI: 10.1111/apt.12136.
198. Allocca M, Fiorino G, Danese S. Commentary: Antibodies reacting with the infliximab Fab portion - Something new? *Aliment Pharmacol Ther*; 38. Epub ahead of print 2013. DOI: 10.1111/apt.12401.
199. Allocca M, Fiorino G, Danese S. Cross-sectional imaging modalities in Crohn's disease. *Dig Dis* 2013; 31: 199–201.
200. Jovani M, Fiorino G, Danese S. Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside. *Curr Drug Targets*; 14. Epub ahead of print 2013. DOI: 10.2174/13894501113149990170.
201. Cesarini M, Fiorino G. Leukocyte traffic control: A novel therapeutic strategy for inflammatory bowel disease - An update. *Expert Rev Clin Immunol*; 9. Epub ahead of print 2013. DOI: 10.1586/eci.13.11.
202. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study. *Inflamm Bowel Dis*; 18. Epub ahead of print 2012. DOI: 10.1002/ibd.21800.
203. Fiorino G, Bonifacio C, Malesci A, et al. MRI in Crohn's disease-current and future clinical applications. *Nat Rev Gastroenterol Hepatol*; 9. Epub ahead of print 2012. DOI: 10.1038/nrgastro.2011.214.
204. Fiorino G, Cesarini M, Malesci A, et al. The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease. *Curr Drug Targets*; 13. Epub ahead of print 2012. DOI: 10.2174/138945012802429651.
205. Chevaux J-B, Fiorino G, Frédéric M, et al. Capsule endoscopy in Crohn's disease. *Curr Drug Targets*; 13. Epub ahead of print 2012. DOI: 10.2174/138945012802429732.
206. De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: More effective and less side effects? *Dig Dis*; 30. Epub ahead of print 2012. DOI: 10.1159/000338128.
207. Fiorino G, Peyrin-Biroulet L, Danese S. Bowel damage assessment in Crohn's disease by magnetic resonance imaging. *Curr Drug Targets*; 13. Epub ahead of print 2012. DOI: 10.2174/138945012802429705.
208. Danese S, Fiorino G, Rutella S. Regulatory T-cell therapy for Crohn's disease: In vivo veritas. *Gastroenterology*; 143. Epub ahead of print 2012. DOI: 10.1053/j.gastro.2012.09.019.
209. Rahier JF, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. *Gut* 2011; 60: 456–462.
210. Rahier JF, Papay P, Salleron J, et al. Influenza A (H1N1)v infection in patients with inflammatory bowel disease: A case series. *Alimentary Pharmacology and Therapeutics* 2011; 33: 499–500.
211. Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. *Aliment Pharmacol Ther* 2011; 33: 349–357.
212. Rutella S, Fiorino G, Vetrano S, et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with crohn's disease. *Am J Gastroenterol* 2011; 106: 762–770.
213. Fiorino G, Bonifacio C, Peyrin-Biroulet L, et al. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's

- disease. *Inflamm Bowel Dis* 2011; 17: 1073–1080.
214. Fabro M, Szabo H, Terrosu G, et al. Acute Severe Colitis: Infliximab and/or Cyclosporine? *Curr Drug Targets* 2011; 12: 1448–1453.
 215. Fiorino G, Szabò H, Fries W, et al. Adalimumab in crohn's disease: Tips and tricks after 5 years of clinical experience. *Curr Med Chem*; 18. Epub ahead of print 2011. DOI: 10.2174/092986711795029726.
 216. Fiorino G, Peyrin-Biroulet L, Repici A, et al. Adalimumab in ulcerative colitis: Hypes and hopes. *Expert Opinion on Biological Therapy* 2011; 11: 109–116.
 217. Spinelli A, Sacchi M, Fiorino G, et al. Risk of postoperative recurrence and postoperative management of Crohn's disease. *World J Gastroenterol* 2011; 17: 3213–3219.
 218. Nunes T, Fiorino G, Danese S, et al. Familial aggregation in inflammatory bowel disease: Is it genes or environment? *World J Gastroenterol* 2011; 17: 2715–2722.
 219. Fiorino G, Cesarini M, Indriolo A, et al. Mucosal Healing in Ulcerative Colitis: Where do we Stand? *Curr Drug Targets* 2011; 12: 1417–1423.
 220. Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF- α therapy. *Alimentary Pharmacology and Therapeutics* 2011; 34: 1–10.
 221. Fiorino G, Cesarini M, Danese S. Biological Therapy for Ulcerative Colitis: What is after Anti-TNF. *Curr Drug Targets* 2011; 12: 1433–1439.
 222. Annunziata ML, Bossa F, Bozzi R, et al. The Italian clinical experience with adalimumab in Crohn's disease: Eleven clinical cases. *Dig Liver Dis Suppl* 2010; 4: 1–3.
 223. Danese S, Fiorino G, Angelucci E, et al. Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: A pilot study. *World J Gastroenterol* 2010; 16: 2396–2400.
 224. Szabò H, Fiorino G, Spinelli A, et al. Review article: Anti-fibrotic agents for the treatment of Crohn's disease - Lessons learnt from other diseases. *Alimentary Pharmacology and Therapeutics* 2010; 31: 189–201.
 225. Fiorino G, Fries W, De La Rue SA, et al. New Drug Delivery Systems in Inflammatory Bowel Disease: MMX™ and Tailored Delivery to the Gut. *Curr Med Chem* 2010; 17: 1851–1857.
 226. Fiorino G, Correale C, Fries W, et al. Leukocyte traffic control: A novel therapeutic strategy for inflammatory bowel disease. *Expert Review of Clinical Immunology* 2010; 6: 567–572.
 227. Fiorino G, Roviola S, Correale C, et al. Emerging Biologics in the Treatment of Inflammatory Bowel Disease: What is Around the Corner? *Curr Drug Targets* 2010; 11: 249–260.
 228. Fiorino G, Repici A, Malesci A, et al. Adalimumab is effective in achieving clinical and endoscopic long-term deep remission: A case report. *Dig Liver Dis Suppl* 2010; 4: 25–27.
 229. Szabò H, Fiorino G, Danese S. Heat shock protein 47 is a new candidate molecule as anti-fibrotic treatment of Crohn's disease: Authors' reply. *Aliment Pharmacol Ther* 2010; 31: 927–928.
 230. Sorrentino D, Paviotti A, Fiorino G. Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows. *Curr Drug Targets* 2010; 11: 219–226.
 231. Fiorino G, Allez M, Malesci A, et al. Review article: Anti TNF- α induced psoriasis in patients with inflammatory bowel disease. *Alimentary*

Pharmacology and Therapeutics 2009; 29: 921–927.

232. Fiorino G, Danese S, Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases. In: *Clinical Update on Inflammatory Disorders of the Gastrointestinal Tract*. 2009, pp. 95–107.
233. Cesarini M, Angelucci E, Fiorino G, et al. Postoperative recurrence of Crohn's disease and videocapsule endoscopy: It is necessary to leave no stone unturned. *Inflammatory Bowel Diseases* 2008; 14: 1165–1166.